About
About Hebei Changshan Biochemical Pharmaceutical Co., Ltd
Hebei Changshan Biochemical Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, marketing, and sale of drugs for cardiovascular, cerebrovascular, diabetes, and cancer in China and internationally. It offers heparin sodium, calcium, and lithium, as well as heparinoid, LMW heparins, and sodium hyaluronate; dalteparin sodium, enoxaparin sodium, nadroparin calcium, and heparin sodium injections, as well as sildenafil citrate tablet; and albenatide. The company is also involved in technology development; consulting; transfer services; investment and management of medical service projects; wholesale and retail of pharmaceuticals; and diagnosis services. It exports its products to the United States, Germany, France, Italy, Spain, South Korea, Japan, Russia, India, the Philippines, and other countries. The company was founded in 1992 and is based in Shijiazhuang, China.
Visit company website
5 years, 5 months ago
Hebei Changshan Biochemical Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 2.3% below its 200 day moving average.
From a valuation standpoint, the stock is 72.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.7.
Hebei Changshan Biochemical Pharmaceutical Co., Ltd's total revenue rose by 19.4% to $628M since the same quarter in the previous year.
Its net income has increased by 4.2% to $74M since the same quarter in the previous year.
Finally, its free cash flow fell by 248.4% to $-32M since the same quarter in the previous year.
Based on the above factors, Hebei Changshan Biochemical Pharmaceutical Co., Ltd gets an overall score of 3/5.